Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 3;79(17):1704-1712.
doi: 10.1016/j.jacc.2022.02.034.

The National Cardiovascular Data Registry Data Quality Program 2020: JACC State-of-the-Art Review

David J Malenka  1 , Deepak L Bhatt  2 , Steven M Bradley  3 , David M Shahian  4 , Jasmine Draoui  5 , Claire A Segawa  5 , Christina Koutras  5 , Jinnette D Abbott  6 , James C Blankenship  7 , Robert Vincent  8 , John Windle  9 , Thomas T Tsai  10 , Jeptha Curtis  11 , Matthew Roe  12 , Frederick A Masoudi  13
Affiliations
Free article
Review

The National Cardiovascular Data Registry Data Quality Program 2020: JACC State-of-the-Art Review

David J Malenka et al. J Am Coll Cardiol. .
Free article

Abstract

The National Cardiovascular Data Registry is a group of registries maintained by the American College of Cardiology Foundation. These registries are used by a diverse constituency to improve the quality and outcomes of cardiovascular care, to assess the safety and effectiveness of new therapies, and for research. To achieve these goals, registry data must be complete and reliable. In this article, we review the process of National Cardiovascular Data Registry data collection, assess data completeness and integrity, and report on the current state of the data. Registry data are complete. Accuracy is very good but variable, and there is room for improvement. Knowledge of the quality of data is essential to ensuring its appropriate use.

Keywords: American College of Cardiology; NCDR; audit; data quality program; quality; registry.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Malenka has served as chair of the National Cardiovascular Data Registry (NCDR) Data Quality Subcommittee of the NCDR Science and Quality Oversight Committee; and has served as a consultant for Anthem. Dr Bhatt has served on the Advisory Board of Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Level Ex, Medscape Cardiology, MyoKardia, PhaseBio, PLx Pharma, and Regado Biosciences; has served on the Board of Directors of Boston Veterans Affairs Research Institute, Society of Cardiovascular Patient Care, and TobeSoft; has served as chair of the American Heart Association Quality Oversight Committee; has served on the Data Monitoring Committee of Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi-Sankyo), and Population Health Research Institute; has received honoraria from the American College of Cardiology (senior associate editor, Clinical Trials and News,” vice chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee, funded by Boehringer Ingelheim; AEGIS-II executive committee, funded by CSL Behring), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor-in-chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (cochair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (continuing medical education steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (continuing medical education steering committees); has served as deputy editor for Clinical Cardiology, chair of the NCDR-ACTION Registry Steering Committee, and chair of the VA CART Research and Publications Committee; has received research funding from Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, MyoKardia, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, and The Medicines Company; has received royalties from Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); has served as site coinvestigator for Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), and Svelte; has served as trustee for the American College of Cardiology; and has conducted unfunded research for FlowCo, Merck, Novo Nordisk, and Takeda. Dr Abbott has received grant/research/clinical trial support from AstraZeneca (coronary artery disease), Bristol Myers Squibb (atrial fibrillation), Abbott (percutaneous coronary intervention), Biosensors Research USA (percutaneous coronary intervention), CSL Behring, LLC (hyperlipidemia), Sinomed (percutaneous coronary intervention); and has served as a consultant/on the Advisory Board for Recor (renal denervation), Philips (artificial intelligence, fellowship education), and Boston Scientific (coronary physiology). Dr Curtis receives salary support under contract with the National Cardiovascular Data Registry to provide analytic services; receives salary support from the Centers for Medicare and Medicaid Services to develop and maintain performance measures that are used for public reporting; has a contract with the American College of Cardiology for his role as senior medical officer, National Cardiovascular Data Registry; and holds equity interest in Medtronic. Dr Roe has received stock options from Verana Health (since February, 2020); has received research grant funding from Sanofi, AstraZeneca, Patient Centered Outcomes Research Institute, Ferring Pharmaceuticals, MyoKardia, Familial Hypercholesterolemia Foundation, and Bayer; has received personal fees and honoraria from AstraZeneca (consulting), Amgen (consulting), Cytokinetics (consulting), Eli Lilly (consulting, service on a clinical endpoint adjudication committee), Roche-Genentech (service on a data safety monitoring committee), Janssen Pharmaceuticals (consulting), Regeneron (consulting, service on a data safety monitoring committee), Novo Nordisk (service on a clinical endpoint adjudication committee), Pfizer (consulting), Sanofi (service on a clinical endpoint adjudication committee), Signal Path (consulting), and Elsevier Publishers (service as an associate editor for the American Heart Journal). Dr Masoudi has a contract with the American College of Cardiology for his role as chief scientific advisor, National Cardiovascular Data Registry. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

LinkOut - more resources